Shares in 4DMedical Ltd (ASX: 4DX) have been placed in a trading halt on Tuesday as the company seeks to raise fresh capital from investors.
According to the Australian Financial Review, term sheets are being circulated to investors offering $150 million worth of new shares at a price of $3.80 per share.
This would be a significant discount to the $4.29 the shares last changed hands for, with 4DMedical valued at $2.29 billion at that price.
Shares in the company have made significant gains over the past year, increasing from a low of 22.5 cents to a recent high of $4.84.
Key approval bolstering share price
Most of 4DMedical's gains have come since August, when the company achieved US Food and Drug Administration approval for its CT:VQ technology, which is used in lung imaging.
Since winning approval, the company has been successful in signing contracts with four major health systems in the US, with one of those contracts, with UC San Diego Health (UCSD), secured just last week.
The company said in relation to that contract:
UCSD has commenced clinical use of CT:VQ under a structured launch framework whereby introductory pricing will apply through March 31, supporting early clinical adoption and workflow establishment, before transitioning to full commercial terms. UCSD joins Stanford University, University of Miami, and Cleveland Clinic as the fourth U.S. academic medical centre (AMC) to deploy CT:VQ for clinical use. This expanding network of leading AMCs powers 4DMedical's strategic approach of establishing reference sites at the nation's most prestigious institutions, creating a powerful foundation for broader market adoption. These deployments demonstrate the compelling clinical value proposition of CT:VQ™: eliminating the need for radioisotope and contrast administration, providing superior image resolution compared to nuclear medicine, seamlessly integrating into existing CT imaging workflows, and enabling access to reimbursement pathways that support sustainable clinical adoption.
4D Medical founder and Managing Director Andreas Fouras said the new contract win was a "powerful validation" of the company's technology.
He added:
In just over four months since FDA clearance, we've established CT:VQ at four of America's leading academic medical centres: Stanford, University of Miami, Cleveland Clinic, and now UCSD. This rapid adoption by elite institutions demonstrates both the transformative potential of CT:VQ™ and the strength of our go-to-market execution. These prestigious AMCs serve as powerful anchors for our commercialisation strategy. Combined with our Philips partnership and growing commercial pipeline, we are building unstoppable momentum as we establish CT:VQ™ as the new standard of care in pulmonary imaging.
4DMedical shares are expected to return to trade by Thursday morning at the latest.
